Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · March 20, 2024

Efficacy and Safety of Roflumilast Foam 0.3% in Adolescents and Adults With Seborrheic Dermatitis

Journal of the American Academy of Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
J Am Acad Dermatol 2024 Jan 20;[EPub Ahead of Print], A Blauvelt, ZD Draelos, L Stein Gold, J Alonso-Llamazares, N Bhatia, J DuBois, SB Forman, M Gooderham, L Green, ST Guenthner, AA Hebert, E Lain, AY Moore, KA Papp, M Zirwas, S Kato, S Snyder, D Krupa, P Burnett, DR Berk, DH Chu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading